Researchers at the University of Cambridge and its spin-out DIOSynVax reported preclinical results for an AI-guided broad-spectrum bird flu mRNA vaccine, DVX-panH5Nx, targeting multiple H5Nx variants. In animal studies described in Cell Reports Medicine, the vaccine achieved complete protection against globally circulating, diverse H5Nx variants. The team contrasted the approach with stockpiled vaccines designed for specific emergent variants, reporting that those existing formulations protected only about half of animals exposed across multiple H5N1 variants. The work frames AI-guided engineering as a way to anticipate viral evolution rather than react after a strain locks in. If the protection and breadth hold through additional translational steps, the program could strengthen pandemic preparedness by shifting vaccine strategy toward multi-antigen designs that maintain coverage across variant sets. The study also adds to a growing body of preclinical evidence for AI-assisted vaccine platforms intended to create resilient immunity for zoonotic threats.